These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29209571)

  • 21. Tumoral melanosis after immunotherapy with pembrolizumab - a response sign mimicking melanoma.
    Relvas M; Alves F; Mariano A; Cardoso J; Coutinho I
    Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
    Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
    J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study.
    de la Cruz-Merino L; Gion M; Cruz-Jurado J; Quiroga V; Andrés R; Moreno F; Alonso-Romero JL; Ramos M; Holgado E; Cortés J; López-Miranda E; Henao-Carrasco F; Palazón-Carrión N; Rodríguez LM; Ceballos I; Casas M; Benito S; Chiesa M; Bezares S; Caballero R; Jiménez-Cortegana C; Sánchez-Margalet V; Rojo F
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction.
    Kunimasa K; Isei T; Nakamura H; Kimura M; Inoue T; Tamiya M; Nishino K; Kumagai T; Nakatsuka SI; Endo H; Inoue M; Imamura F
    Invest New Drugs; 2018 Dec; 36(6):1138-1142. PubMed ID: 29947012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
    Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
    Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer.
    İyikesici MS; Slocum AK; Slocum A; Berkarda FB; Kalamian M; Seyfried TN
    Cureus; 2017 Jul; 9(7):e1445. PubMed ID: 28924531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy.
    Silva NN; Eng C
    J Adv Pract Oncol; 2012 May; 3(3):161-9. PubMed ID: 25031942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma.
    Yeku O; Russo AL; Lee H; Spriggs D
    J Transl Med; 2020 Sep; 18(1):350. PubMed ID: 32928237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer.
    Barroso-Sousa R; Krop IE; Trippa L; Tan-Wasielewski Z; Li T; Osmani W; Andrews C; Dillon D; Richardson ET; Pastorello RG; Winer EP; Mittendorf EA; Bellon JR; Schoenfeld JD; Tolaney SM
    Clin Breast Cancer; 2020 Jun; 20(3):238-245. PubMed ID: 32113750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer.
    Montero A; Glück S
    Case Rep Oncol; 2012 Sep; 5(3):687-92. PubMed ID: 23341813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy in Triple-Negative Breast Cancer.
    Emens LA
    Cancer J; 2021 Jan-Feb 01; 27(1):59-66. PubMed ID: 33475294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study.
    Shen L; Qi H; Chen S; Cao F; Xie L; Wu Y; Ma W; Song Z; Yuan H; Zhang T; Li D; Wen X; Chen Q; Li W; Zhang X; Fan W
    Cancer Immunol Immunother; 2020 Sep; 69(9):1713-1724. PubMed ID: 32333081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
    Nanda R; Chow LQ; Dees EC; Berger R; Gupta S; Geva R; Pusztai L; Pathiraja K; Aktan G; Cheng JD; Karantza V; Buisseret L
    J Clin Oncol; 2016 Jul; 34(21):2460-7. PubMed ID: 27138582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
    JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
    Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
    J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.
    Paluch-Shimon S; Friedman E; Berger R; Papa M; Dadiani M; Friedman N; Shabtai M; Zippel D; Gutman M; Golan T; Yosepovich A; Catane R; Modiano T; Kaufman B
    Breast Cancer Res Treat; 2016 May; 157(1):157-65. PubMed ID: 27113739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.
    Pang X; Qian J; Jin H; Zhang L; Lin L; Wang Y; Lei Y; Zhou Z; Li M; Zhang H
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.